All In MedTech

Device Trial Radar · NCT06857708

The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 5, 2025

Primary completion

Sep 1, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Benjamin T. MillerAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 4, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, pilot, parallel group, randomized controlled trial with 1:1 allocation. This will be a single center study coordinated at the Cleveland Clinic Foundation (CCF) Main Campus in Cleveland, Ohio. Data will be collected in a secure manner using REDCap housed at CCF. The study will consist of 2 arms: treatment with Cytal® Wound Matrix 2-Layer and MicroMatrix® (Integra LifeSciences, Plainsboro Township, NJ, U.S.A.) versus standard of care dressings. Wound debridement procedures will be performed by surgical staff at CCF. A co-investigator trained in the application of Cytal® Wound Matrix and MicroMatrix® will apply these treatments as outlined in section 6.1.2 Administration. This study will be conducted with IRB approval and written informed consent of each participant enrolled. The trial will be registered at ClinicalTrials.gov before the first participant is enrolled.

Conditions

  • Necrotizing Fascitis
  • Necrotizing Soft Tissue Infection

Interventions

  • Cytal® Wound MatrixDevice

    This is the only study to use this intervention in necrotizing soft tissue wounds

  • MicroMatrix®Device

    This is the only study to use this intervention in necrotizing soft tissue wounds

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to readiness for grafting of the wound bedTime frame: From randomization to readiness for grating, up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.